Abstract 190P
Background
Perioperative chemotherapy(CT) for resectable locally advanced gastric or gastroesophageal junction(G/GEJ) adenocarcinoma has favourable outcomes. Immune checkpoint inhibitors(ICIs) combined with CT have some efficacy in advanced G/GEJ adenocarcinoma. However, the application of ICIs in resectable locally advanced G/GEJ adenocarcinoma remains to be explored. Here, this clinical trial evaluates efficacy and safety of perioperative ICI(Camrelizumab) +CT(XELOX) in resectable locally advanced G/GEJ adenocarcinoma.
Methods
Treatment-naive patients(pts) with cT3-4aN1-3M0 resectable locally advanced G/GEJ adenocarcinoma were recruited to receive Camrelizumab(200mg, iv) on D1, Oxaliplatin(130 mg/m2, iv) on D1 and Capecitabine(1000 mg/m2, po, bid) on D1∼14 Q3W for 4 cycles, followed by surgery and adjuvant Camrelizumab+CT Q3W for 4 cycles. The primary endpoint was pCR rate. The secondary endpoints were MPR rate, ORR, EFS, DFS, safety and feasibility of surgery. The exploratory endpoint was correlation between PD-L1 and TMB expression and efficacy.
Results
From 9/2020 to 1/2023, 46 pts were enrolled, received and completed neoadjuvant treatment, 43 of which had underwent D2 resection. 38 pts received, but 35 pts completed adjuvant treatment. In the ITT analysis set, pCR(TRG1a) occurred in 9 pts(19.6%, 95%CI: 9.9%-34.4%), and MPR(TRG1a/b) occurred in 25 pts(54.3%, 95%CI: 39.2%-68.8%). TRG1b, TRG2 and TRG3 were observed in 16(34.8%), 12 (26.1%) and 6(13.0%) pts, respectively. ORR was 69.6%(95%CI: 54.1%-81.2%), of which 12 pts achieved CR and 20 pts achieved PR. 1-year EFS and DFS achieved 93.101% and 93.108% respectively. Treatment-related adverse events(TRAE) occurred in 91.3% pts, and grade 3 TRAE occurred in 19.6% pts. No grade 4–5 TRAEs were observed. The toxicity and post-surgery complications were limited. Surgical feasibility was not affected.
Conclusions
Among patients with resectable locally advanced G/GEJ adenocarcinoma, neoadjuvant Camrelizumab combined with CT followed by surgery and adjuvant treatment demonstrated good efficacy and safety, providing a new treatment option for locally advanced G/GEJ adenocarcinoma.
Clinical trial identification
NCT05715632.
Editorial acknowledgement
Legal entity responsible for the study
the authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract